Cover Image
市場調查報告書

美國的培養皮膚(皮膚替代品)市場預測

United States Tissue Engineered - Skin Substitutes Market Outlook to 2024

出版商 GlobalData 商品編碼 316774
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
美國的培養皮膚(皮膚替代品)市場預測 United States Tissue Engineered - Skin Substitutes Market Outlook to 2024
出版日期: 2017年09月04日 內容資訊: 英文 71 Pages
簡介

本報告提供美國的培養皮膚(皮膚替代品)市場相關調查分析,提供您各市場區隔的市場規模資料,年度的市場收益·數量·平均銷售價格,企業佔有率·流通佔有率資料,主要企業簡介等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 美國的培養皮膚(皮膚替代品)市場

  • 培養皮膚(皮膚替代品)市場,美國,收益實際成果($m)
  • 培養皮膚(皮膚替代品)市場,美國,收益預測($m)
    • 生物學的皮膚替代品市場,美國,收益實際成果($m),各市場區隔
      • 異體移植片市場,美國,收益實際成果($m),各子市場區隔
    • 生物學的皮膚替代品市場,美國,收益預測($m),各市場區隔
      • 異體移植片市場,美國,收益預測($m),各子市場區隔
  • 培養皮膚(皮膚替代品)市場,美國,數量實際成果
  • 培養皮膚(皮膚替代品)市場,美國,數量預測
    • 生物學的皮膚替代品市場,美國,數量實際成果,各市場區隔
      • 異體移植片市場,美國,數量實際成果,各子市場區隔
    • 生物學的皮膚替代品市場,美國,數量預測,各市場區隔
      • 異體移植片市場,美國,數量預測,各子市場區隔
  • 培養皮膚(皮膚替代品)市場,美國,平均銷售價格($)
  • 培養皮膚(皮膚替代品)市場,美國,各收益的流通佔有率($m)
  • 培養皮膚(皮膚替代品)市場,美國,各收益的企業佔有率($m)

第4章 美國的主要企業概要,培養皮膚(皮膚替代品)市場

  • Organogenesis Inc.
  • Shire Plc
  • Kinetic Concepts, Inc.
  • Smith & Nephew Plc
  • Integra LifeSciences Holdings Corporation
  • Covidien plc
  • 4.7Molnlycke Health Care AB
  • BSN medical GmbH

第5章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDMECC2619DB

GlobalData's new report, "United States Tissue Engineered - Skin Substitutes Market Outlook to 2024", provides key market data on the United States Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Biologic Skin Substitutes, Biosynthetic Skin Substitutes and Synthetic Skin Substitutes.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Tissue Engineered - Skin Substitutes market segments - Biologic Skin Substitutes, Biosynthetic Skin Substitutes and Synthetic Skin Substitutes.
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
  • 2017 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the United States Tissue Engineered - Skin Substitutes market.
  • Key players covered include Ethicon US LLC, Baxter International Inc, Integra LifeSciences Corp and C. R. Bard Inc.

Reasons to buy

  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Introduction 5

  • 2.1 What Is This Report About? 5
  • 2.2 Tissue Engineered - Skin Substitutes Market Segmentation 5
  • 2.3 Definitions of Markets Covered in the Report 6

3 Tissue Engineered - Skin Substitutes Market, United States 7

  • 3.1 Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), 2010-2017 7
  • 3.2 Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), 2017-2024 9
    • 3.2.1 Biologic Skin Substitutes Market, United States, Revenue ($m), by Segment, 2010-2017 11
    • 3.2.2 Biologic Skin Substitutes Market, United States, Revenue ($m), by Segment, 2017-2024 13
  • 3.3 Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), 2010-2017 15
  • 3.4 Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), 2017-2024 17
    • 3.4.1 Biologic Skin Substitutes Market, United States, Volume (Units), by Segment, 2010-2017 19
    • 3.4.2 Biologic Skin Substitutes Market, United States, Volume (Units), by Segment, 2017-2024 21
  • 3.5 Tissue Engineered - Skin Substitutes Market, United States, Average Price ($), 2010-2024 23
  • 3.6 Tissue Engineered - Skin Substitutes Market, United States, Distribution Share by Revenue ($m), 2017 24
  • 3.7 Tissue Engineered - Skin Substitutes Market, United States, Company Share by Revenue ($m), 2017 25

4 Overview of Key Companies in United States, Tissue Engineered - Skin Substitutes Market 27

  • 4.1 Ethicon US LLC 27
    • 4.1.1 Company Overview 27
  • 4.2 Baxter International Inc 27
    • 4.2.1 Company Overview 27
  • 4.3 C. R. Bard Inc 27
    • 4.3.1 Company Overview 27
  • 4.4 CryoLife Inc 28
    • 4.4.1 Company Overview 28
  • 4.5 Integra LifeSciences Corp 28
    • 4.5.1 Company Overview 28

5 Tissue Engineered - Skin Substitutes Market Pipeline Products 29

6 Financial Deals Landscape 30

  • 6.1 Acquisition 30
    • 6.1.1 Allergan Acquires LifeCell from Acelity for USD2.9 Billion 30
  • 6.2 Equity Offerings 32
    • 6.2.1 RenovaCare Raises USD1 Million in Private Placement of Units 32
    • 6.2.2 Biostage Raises USD8 Million Public Offering of Shares 33
  • 6.3 Partnerships 34
    • 6.3.1 Progenerative Medical Enters into Licensing Agreement with Kinetic Concepts 34
  • 6.4 Venture Financing 35
    • 6.4.1 Saba Labs Raises USD0.3 Million in Venture Financing 35
    • 6.4.2 Organogenesis Raises USD20 Million in Venture Financing 36

7 Recent Developments 37

  • 7.1 Corporate Communications 37
    • 7.1.1 Jul 27, 2017: Anika Announces Appointment of Joseph Darling as President 37
    • 7.1.2 Jun 09, 2017: Acera Surgical appoints new board member 37
    • 7.1.3 Apr 18, 2017: Biostage Appoints Stephen F. Badylak DVM, PhD, MD, as Co-Chairman of Scientific Advisory Board 38
    • 7.1.4 Mar 19, 2017: MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors 38
    • 7.1.5 Sep 19, 2016: Organogenesis Announces New Chief Financial Officer 39
  • 7.2 Financial Announcements 40
    • 7.2.1 Aug 14, 2017: Biostage Reports 2017 Second Quarter Financial Results 40
    • 7.2.2 Jul 26, 2017: MiMedx Announces Record Results For The Second Quarter Of 2017 And Raises Full Year Revenue Guidance 41
    • 7.2.3 Jul 26, 2017: Anika Reports Strong Second Quarter 2017 Financial Results 43
    • 7.2.4 Jul 13, 2017: MiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range 44
    • 7.2.5 May 11, 2017: Biostage Reports 2017 First Quarter Financial Results and Provides Business Update 45
    • 7.2.6 May 03, 2017: Anika Reports First Quarter 2017 Financial Results 46
    • 7.2.7 Apr 28, 2017: MiMedx Announces Record Results For First Quarter Of 2017 47
    • 7.2.8 Apr 13, 2017: MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance 49
    • 7.2.9 Mar 09, 2017: Biostage Reports 2016 Financial Results and Provides Business Update 49
    • 7.2.10 Feb 23, 2017: MiMedx Announces 2016 Record Results 51
    • 7.2.11 Feb 15, 2017: Anika Reports Fourth Quarter and Full Year 2016 Financial Results 53
    • 7.2.12 Feb 15, 2017: Anika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 53
    • 7.2.13 Jan 09, 2017: MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance 54
    • 7.2.14 Dec 16, 2016: MiMedx 2017 Guidance Forecasts Revenue Growth In Excess Of 21% And Operating Earnings Growth In Excess Of 90% 56
    • 7.2.15 Nov 10, 2016: Biostage Reports 2016 Third Quarter Financial Results and Provides Business Update 57
    • 7.2.16 Oct 27, 2016: MiMedx Announces Third Quarter 2016 Results 58
    • 7.2.17 Oct 26, 2016: Anika Reports Third Quarter 2016 Financial Results 60
    • 7.2.18 Oct 10, 2016: MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance 61
  • 7.3 Other Significant Developments 62
    • 7.3.1 Jul 05, 2017: MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down 62
    • 7.3.2 Sep 06, 2016: MiMedx Reaffirms Q3 and Full Year 2016 Guidance 62
  • 7.4 Product News 63
    • 7.4.1 Nov 03, 2016: MiMedx Announces USP-NF Monograph For dHACM Allografts Has Published 63
    • 7.4.2 Sep 12, 2016: Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair 63

8 Appendix 65

  • 8.1 Research Methodology 66
    • 8.1.1 Coverage 66
    • 8.1.2 Secondary Research 66
    • 8.1.3 Primary Research 67
    • 8.1.4 Market Modeling and Forecasting 68
    • 8.1.5 Company Share Analysis 69
    • 8.1.6 Distribution Share Analysis 70
    • 8.1.7 Benchmarking 70
  • 8.2 GlobalData Consulting 70
  • 8.3 Contact Us 71
  • 8.4 Disclaimer 71

List of Tables

1.1 List of Tables

  • Table 1: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 8
  • Table 2: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 10
  • Table 3: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 12
  • Table 4: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 14
  • Table 5: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 16
  • Table 6: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 18
  • Table 7: Biologic Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 20
  • Table 8: Biologic Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 22
  • Table 9: Tissue Engineered - Skin Substitutes Market, United States, Average Price ($) Historic, 2010-2017 23
  • Table 10: Tissue Engineered - Skin Substitutes Market, United States, Average Price ($), Forecast, 2017-2024 23
  • Table 11: Tissue Engineered - Skin Substitutes Market, United States, Distribution Share by Revenue ($m), USD Constant, 2017 24
  • Table 12: Tissue Engineered - Skin Substitutes Market, United States, Company Share by Revenue ($m), USD Constant, 2017 26
  • Table 13: Tissue Engineered - Skin Substitutes Market Pipeline Products 29
  • Table 14: Allergan Acquires LifeCell from Acelity for USD2.9 Billion 30
  • Table 15: RenovaCare Raises USD1 Million in Private Placement of Units 32
  • Table 16: Biostage Raises USD8 Million Public Offering of Shares 33
  • Table 17: Progenerative Medical Enters into Licensing Agreement with Kinetic Concepts 34
  • Table 18: Saba Labs Raises USD0.3 Million in Venture Financing 35
  • Table 19: Organogenesis Raises USD20 Million in Venture Financing 36
  • Table 20: Total Number of Primary Research Participants, Wound Care Management Market, by Country 68

List of Figures

1.2 List of Figures

  • Figure 1: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 7
  • Figure 2: Tissue Engineered - Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 9
  • Figure 3: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 11
  • Figure 4: Biologic Skin Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 13
  • Figure 5: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 15
  • Figure 6: Tissue Engineered - Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 17
  • Figure 7: Biologic Skin Substitutes Market, United States, Volume (Units), Historic, 2010-2017 19
  • Figure 8: Biologic Skin Substitutes Market, United States, Volume (Units), Forecast, 2017-2024 21
  • Figure 9: Tissue Engineered - Skin Substitutes Market, United States, Company Share (%) 2017 25
Back to Top